Quell Therapeutics Overview

  • Year Founded
  • 2019

Year Founded

  • Status
  • Private

  • Employees
  • 150

Employees

  • Latest Deal Type
  • Series A

  • Latest Deal Amount
  • $24.7M

  • Investors
  • 17

Quell Therapeutics General Information

Description

Developer of engineered regulatory cell therapies designed for immune-mediated diseases. The company's therapies feature a multi-modular engineering approach, phenotype-lock technology, scalable manufacturing, and targeted tissue engraftment, enabling biotechnology and clinical research markets to pursue durable immune-tolerance therapies in transplantation and autoimmune conditions.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 3rd Floor, Translation & Innovation Hub
  • 84 Wood Lane
  • London W12 0BZ
  • England, United Kingdom
+44 020
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 3rd Floor, Translation & Innovation Hub
  • 84 Wood Lane
  • London W12 0BZ
  • England, United Kingdom
+44 020

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Quell Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Early Stage VC (Series A) 09-Jun-2023 $24.7M Completed Clinical Trials - Phase 2
4. Secondary Transaction - Private Completed Clinical Trials - Phase 2
3. Early Stage VC (Series B) 24-Nov-2021 Completed Clinical Trials - Phase 2
2. Early Stage VC 12-Feb-2021 $83.5M $83.5M Completed Clinical Trials - Phase 2
1. University Spin-Out 19-Mar-2019 Completed Startup
To view Quell Therapeutics’s complete valuation and funding history, request access »

Quell Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B Preferred
Series B Preferred
Series A Preferred 46,500,000 $0.000012 $1.24 $1.24 1x $1.24 33.08%
To view Quell Therapeutics’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Quell Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of engineered regulatory cell therapies designed for immune-mediated diseases. The company's therapies feature
Drug Discovery
London, United Kingdom
150 As of 2025

South San Francisco, CA
 

Brisbane, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Quell Therapeutics Competitors (24)

One of Quell Therapeutics’s 24 competitors is TRexBio, a Formerly VC-backed company based in South San Francisco, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
TRexBio Formerly VC-backed South San Francisco, CA
Annexon Biosciences Formerly VC-backed Brisbane, CA
GentiBio Venture Capital-Backed Cambridge, MA
Kyverna Formerly VC-backed Emeryville, CA
Senti Biosciences Holdings Formerly VC-backed South San Francisco, CA
You’re viewing 5 of 24 competitors. Get the full list »

Quell Therapeutics Patents

Quell Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
GB-202509847-D0 Chimeric antigen receptor Pending 20-Jun-2025
GB-202509833-D0 Expression construct Pending 20-Jun-2025
GB-202509839-D0 Expression construct Pending 20-Jun-2025
GB-202509842-D0 Expression construct Pending 20-Jun-2025
GB-202509829-D0 Nucleic acid molecules Pending 20-Jun-2025 A61K40/418
To view Quell Therapeutics’s complete patent history, request access »

Quell Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Quell Therapeutics Investors (17)

Investor Name Investor Type Holding Investor Since Participating Rounds
AstraZeneca Corporation Minority
Revelation Partners Venture Capital Minority
Breakthrough Energy Impact Investing Minority
British Business Bank Lender/Debt Provider Minority
Fidelity Management & Research Company Asset Manager Minority
You’re viewing 5 of 17 investors. Get the full list »

Quell Therapeutics FAQs

  • When was Quell Therapeutics founded?

    Quell Therapeutics was founded in 2019.

  • Where is Quell Therapeutics headquartered?

    Quell Therapeutics is headquartered in London, United Kingdom.

  • What is the size of Quell Therapeutics?

    Quell Therapeutics has 150 total employees.

  • What industry is Quell Therapeutics in?

    Quell Therapeutics’s primary industry is Drug Discovery.

  • Is Quell Therapeutics a private or public company?

    Quell Therapeutics is a Private company.

  • What is the current valuation of Quell Therapeutics?

    The current valuation of Quell Therapeutics is .

  • What is Quell Therapeutics’s current revenue?

    The current revenue for Quell Therapeutics is .

  • How much funding has Quell Therapeutics raised over time?

    Quell Therapeutics has raised $264M.

  • Who are Quell Therapeutics’s investors?

    AstraZeneca, Revelation Partners, Breakthrough Energy, British Business Bank, and Fidelity Management & Research Company are 5 of 17 investors who have invested in Quell Therapeutics.

  • Who are Quell Therapeutics’s competitors?

    TRexBio, Annexon Biosciences, GentiBio, Kyverna, and Senti Biosciences Holdings are some of the 24 competitors of Quell Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process